These Two Biotechs Boast Big EPS Growth Rates

By | August 6, 2015

Scalper1 News

IBD’s Medical-Biomed/Biotech group holds the No. 1 spot on the list of 197 industry groups tracked, as several of its members topped Street forecasts over the past week. Today’s Screen of the Day focuses on Top Fundamentals, stocks with three-year earnings and revenue growth rates of 25% or more. Gilead Sciences (GILD), which has a three-year EPS growth rate of 91%, develops medicine for life-threatening conditions, including cancer, HIV/AIDS and Scalper1 News

Scalper1 News